Recent Advances and New Directions in Cancer Therapy:

“12th Annual California Cancer Consortium Conference”
August 12-14, 2016
The Westin Pasadena
Pasadena, CA

Presented by the California Cancer Consortium
University of California Davis Comprehensive Cancer Center, Sacramento, CA
City of Hope Comprehensive Cancer Center, Duarte, CA
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA
Stanford Cancer Institute, Palo Alto, CA

Program Chairs: Primo N. Lara, Jr., MD; Edward Newman, PhD; Robert Morgan, MD
Steering Committee: Heinz-Josef Lenz, MD; Shivaani Kumar, MD; David Gandara, MD
Course Description:

This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

Educational Objectives:

After participating in this educational activity, you should be able to:

1. Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of many individual tumor types, and identify specific opportunities for therapeutic intervention.

2. Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of your patients with cancer.

3. Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of your patients with cancer.

4. Discuss the new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

Target Audience:

This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.
Needs Assessment

This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently, improve patient outcomes.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Educator Consortium designates this educational activity for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ADD MOC LOGO

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial Relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational Activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

Nursing Continuing Medical Education

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.
Program Chairs:

Primo N. Lara, Jr., MD
Professor of Medicine
University of California Davis School of Medicine
Associate Director for Translational Research
University of California Davis Comprehensive Cancer Center

Edward Newman, PhD
Associate Professor, Molecular Pharmacology
Co-director, Analytical Pharmacology Core Facility
City of Hope Comprehensive Cancer Center

Robert Morgan, MD
Professor of Medicine
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center

Steering Committee:

Heinz-Josef Lenz, MD
Professor of Medicine and Preventive Medicine, Section Head of GI Oncology
University of Southern California, Keck School of Medicine
Associate Director for Clinical Research, University of Southern California Norris Comprehensive Cancer Center

David R. Gandara, MD
Professor of Medicine
University of California Davis School of Medicine
Senior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Shivaani Kumar, MD
Professor of Medicine
Stanford University School of Medicine
**Distinguished Faculty**

Mehrdad Abedi, MD  
Professor of Medicine  
University of California Davis School of Medicine

Christine Brown, PhD  
Associate Research Professor  
City of Hope Comprehensive Cancer Center

Helen Chew, MD  
Professor of Medicine  
University of California Davis School of Medicine

Warren Chow, MD  
Clinical Professor  
City of Hope Comprehensive Cancer Center

Vincent Chung, MD  
Assistant Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center

E. Dimitrios Colevas, MD  
Associate Professor of Medicine  
Stanford University School of Medicine

Mihaela Cristea, MD  
Assistant Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center

Tanya Dorff, MD  
Assistant Professor  
University of Southern California Keck School of Medicine  
Norris Comprehensive Cancer Center

Oliver Dorigo, MD, PhD  
Professor  
Stanford University School of Medicine

Anthony El-Khoueiry, MD  
Associate Professor  
University of Southern California Keck School of Medicine  
Norris Comprehensive Cancer Center

Paul Frankel, PhD  
Staff Scientist, Division of Biostatistics, Department of Information Sciences  
Beckman Research Institute, City of Hope Comprehensive Cancer Center
David R. Gandara, MD  
Professor of Medicine, University of California Davis School of Medicine  
Senior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Barbara Gitlitz, MD  
Associate Professor of Medicine, Keck School of Medicine  
University Southern California Norris Comprehensive Cancer Center

Susan Groshen, PhD  
Professor of Medicine and Director, Biostatistics Core  
University Southern California Norris Comprehensive Cancer Center

Alex Herrera, MD  
Assistant Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center

James Hu, MD  
Assistant Professor of Medicine, Keck School of Medicine  
University Southern California Norris Comprehensive Cancer Center

Brian Jonas, MD, PhD  
Assistant Professor, Division of Hematology/Oncology, University of California Davis School of Medicine

Jae Jung, MD, PhD  
Assistant Professor of Surgery  
City of Hope Comprehensive Cancer Center

Kevin Kelly, MD, PhD  
Associate Professor  
University of Southern California, Keck School of Medicine

Marianna Koczywas, MD  
Clinical Professor of Medicine  
City of Hope Comprehensive Cancer Center

Shivaani Kummar, MD  
Professor of Medicine  
Stanford University School of Medicine

Heinz-Josef Lenz, MD  
Professor of Medicine and Preventive Medicine, Section Head of GI Oncology  
University of Southern California, Keck School of Medicine  
Associate Director for Clinical Research  
University Southern California Norris Comprehensive Cancer Center

Primo N. Lara, Jr., MD  
Professor of Medicine  
University of California Davis School of Medicine
Associate Director for Translational Research, University of California Davis Comprehensive Cancer Center

**Tianhong Li, MD, PhD**
Associate Professor, University of California Davis School of Medicine
University of California Davis Comprehensive Cancer Center

**Jeffery Longmate, PhD**
Professor and Director, Division of Biostatistics, Department of Information Sciences
Beckman Research Institute, City of Hope Comprehensive Cancer Center

**Philip Mack, PhD**
Associate Professor of Medicine, University of California Davis School of Medicine
Director, Cancer Molecular Pharmacology, University of California Davis Comprehensive Cancer Center

**Guido Marcucci, MD**
Professor of Medicine, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

**Kim Margolin, MD**
Professor of Medicine, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

**Robert Morgan, MD**
Professor of Medicine, Department of Medical Oncology and Therapeutics Research
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center

**Edward Newman, PhD**
Associate Professor, Cancer Biology
Co-director, Analytical Pharmacology Core Facility
City of Hope Comprehensive Cancer Center

**David Quinn, MBBS, PhD**
Associate Professor and Head, Section of GU Medical Oncology, USC Keck School of Medicine
Leader, Developmental Therapeutics Program, University of Southern California Norris Comprehensive Cancer Center

**Jonathan Riess, MD, MS**
Assistant Professor
University of California Davis School of Medicine

**Aaron Rosenberg, MD, MS**
Assistant Professor
University of California Davis School of Medicine

**Sarmad Sadeghi, MD, PhD**
Ravi Salgia, MD, PhD  
Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center

Thomas Semrad, MD  
Assistant Professor, UC Davis School of Medicine  
University of California Davis Comprehensive Cancer Center

George Sledge, MD  
Professor of Medicine and Chief, Division of Oncology  
Stanford University School of Medicine

George Somlo, MD  
Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center

Sandya Srinivas, MD  
Associate Professor  
Stanford University School of Medicine

Timothy Synold, PharmD  
Director, Analytical Pharmacology Core Facility  
Associate Professor, Cancer Biology  
City of Hope Comprehensive Cancer Center

Joseph Tuscano, MD  
Professor of Medicine, Division of Hematology and Oncology, UC Davis School of Medicine  
University of California Davis Comprehensive Cancer Center

Przemyslaw Twardowski, MD  
Associate Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center
Friday, August 12th, 2016

1:30 - 3:00 pm  Registration & Visit Exhibits

3:00 pm  Welcome and Introductions

3:05 pm  Pre-session Survey/MOC Pre-Questionnaire

Session 1: Inhibition of Signal Transduction and Angiogenesis Pathways

Chairs: Primo Lara (UC Davis) and Edward Newman (City of Hope)

3:15 pm  EGFR Inhibitors: State of the Art
Marianna Koczywas, City of Hope

3:35 pm  Question-and-Answer Session

3:40 pm  MET Pathway Inhibitors
Ravi Salgia, City of Hope

4:00 pm  Question-and-Answer Session

4:05 pm  FGF and FGFR as Therapeutic Targets
Philip C. Mack, UC Davis

4:25 pm  Question-and-Answer Session

4:30 pm  Angiogenesis Inhibitors
Oliver Dorigo, Stanford

4:50 pm  Question-and-Answer Session

4:55 pm  mTOR inhibitors: Latest and Greatest
Barbara Gitlitz, USC

5:15 pm  Question-and-Answer Session

5:20 PM  Refreshment Break & Visit Exhibits

Session 2: Clinical Trial Design

Chairs: Susan Groshen (USC) and Paul Frankel (City of Hope)

5:35 pm  Phase I Designs: Is the Answer You Get the One You Want?
5:50 pm  Question-and-Answer Session
5:55 pm  How to Select the Right Phase 2 Endpoints
         Susan Groshen, USC
6:10 pm  Question-and-Answer Session
6:15 pm  Phase Ib Trials with Expansion Cohorts and
         Phase 2 trials: a Case for Seamless Study Design
         Jeff Longmate, City of Hope
6:30 pm  Question-and-Answer Session
6:35 pm  Roundtable Discussion: Statistical Considerations in the ET-CTN era
         Moderator: Edward Newman (City of Hope)

Participants: Jeff Longmate, Paul Frankel, Susan Groshen, David Gandara
6:55 pm  Post-session Survey
7:00-8:00 pm Wine and Cheese Welcome Reception & Visit Exhibits

Saturday, August 13th, 2016
7:30 am  Registration, Refreshments & Visit Exhibits
8:00 – 8:45 am  Breakfast & Learn Symposia (non CME)
9:00 am  Introduction
9:05 am  Pre-session Survey

Session 3: Cancer Immunotherapy
Chair: Tianhong Li (UC Davis) and Primo Lara (UC Davis)
9:10 am  Immunology for Dummies: A Review
         Kim Margolin, City of Hope
9:30 am  Question-and-Answer Session
9:35 am  Checkpoint inhibitor therapy
9:55 am Question-and-Answer Session

10:00 am Cell Based Immunotherapy Approaches
Christine Brown, City of Hope

10:20 am Question and Answer

10:25 am Cancer Vaccines
Vincent Chung, City of Hope

10:45 am Question and Answer

Session 4: Lung Cancer

Chairs: Marianna Koczywas (City of Hope) and Jonathan Riess (UC Davis)

10:50 am New Developments in Lung Cancer Therapeutics
David Gandara, UC Davis

11:10 am Question-and-Answer Session

11:15 am Small Cell Lung Cancer and Thymoma: What’s New?
Jonathan Riess, UC Davis

11:35 am Question-and-Answer Session

11:40 am Close Morning Session

11:50 – 12:25 pm Lunch & Learn Symposia (non cme)

12:25 – 12:40 pm Refreshments & Visit Exhibits

Session 5: Gastrointestinal Malignancies

Chairs: Thomas Semrad (UC Davis) and Robert Morgan (City of Hope)

12:40 am Systemic Therapy for Colorectal Carcinoma in the Adjuvant and Metastatic Settings
Heinz-Josef Lenz, USC

1:00 pm Question-and-Answer Session
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:05 pm</td>
<td>New Developments in Esophagogastric and Pancreatic Cancers</td>
<td>Anthony El-Khoueiri, USC</td>
</tr>
<tr>
<td>1:25 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
</tbody>
</table>

Session 6: Hematologic Malignancies

Chair: Brian Jonas (UC Davis) and Guido Marcucci (City of Hope)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 pm</td>
<td>New Developments in Acute Leukemia</td>
<td>Kevin Kelly, USC</td>
</tr>
<tr>
<td>1:50 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>1:55 pm</td>
<td>Multiple Myeloma: Current and Future Directions</td>
<td>Aaron Rosenberg, UC Davis</td>
</tr>
<tr>
<td>2:15 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Chronic Lymphocytic Leukemia: Updates</td>
<td>Alex Herrera, City of Hope</td>
</tr>
<tr>
<td>2:40 pm</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
<tr>
<td>2:45 – 3:00 pm</td>
<td>Refreshment break, Visit Exhibits</td>
<td></td>
</tr>
</tbody>
</table>

Session 7: Genitourinary Malignancies

Chairs: Primo Lara (UC Davis) and Sarmad Sadeghi (USC)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td>Castration Resistant Prostate Cancer Therapy</td>
<td>Tanya Dorff, USC</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>3:25 pm</td>
<td>Updates in Renal Cell Carcinoma Drug Development</td>
<td>Sarmad Sadeghi, USC</td>
</tr>
<tr>
<td>3:45 pm</td>
<td>Question-and-Answer Session</td>
<td></td>
</tr>
<tr>
<td>3:50 pm</td>
<td>Bladder Cancer: Chemotherapy and Beyond!</td>
<td></td>
</tr>
</tbody>
</table>
Session 8: Gynecologic Cancer

Chair: Oliver Dorigo, Stanford

4:15 pm  Management of Ovarian Cancer in 2016
Robert Morgan, City of Hope

4:35 pm  Question-and-Answer Session

4:40 pm  New Approaches to Cervix and Endometrial Cancer
Mihaela Cristea, City of Hope

5:00 pm  Question-and-Answer Session

5:05 pm  Post-session Survey

Refreshments, Visit Exhibits

5:15 – 6:15 pm  CCC Business Meeting (by invitation only)

7:30 – 9:30 pm  CCC Dinner (Newman Residence – by invitation only)

Sunday, August 14th, 2016

7:00 am  Registration, Refreshments & Visit Exhibits

7:15 am – 8:15am  Breakfast & Learn Symposia (non cme)

8:15 am  Introduction

8:20 am  Pre-session Survey

Session 9: Breast Cancer

Chair: George Somlo (City of Hope)

8:25 am  Hormone Receptor Positive Breast Cancer: What’s New?
Helen Chew, UC Davis

8:45 am  Question-and-Answer Session
8:50 am  Triple Negative Breast Cancer: Emerging Strategies
          George Sledge, Stanford
9:10 am  Question-and-Answer Session

Session 10: Rapid Review of Hot New Developments in Specific Tumor Types
Chairs: Warren Chow (City of Hope) and Przemyslaw Twardowski (City of Hope)
9:15 am  Malignant Melanoma and other Cutaneous Tumors
          Jae Jung, City of Hope
9:30 am  Question-and-Answer Session
9:35 am  Malignant Lymphomas
          Joseph Tuscano, UC Davis
9:50 am  Question-and-Answer Session
9:55 am  Soft Tissue Sarcomas
          James Hu, USC
10:10 am Question-and-Answer Session
10:15 am Head and Neck Cancer
          E. Dimitrios Colevas, Stanford
10:20 am Question-and-Answer Session
10:25-10:40 am Refreshment Break & Visit Exhibits

Session 11: Rapid Review of Emerging Therapeutic Strategies in Oncology
Chairs: Tim Synold (City of Hope) and Edward Newman (City of Hope)
10:40 am  Targeting DNA Damage Repair (PARP, ATR inhibitors)
          Shivaani Kummar, Stanford
10:55 am  Question-and-Answer Session
11:00 am  Targeting Heat Shock Proteins
Jonathan Riess, UC Davis
11:15 am  Question-and-Answer Session
11:20 am  Newer Cytotoxics (e.g., eribulin, nab-paclitaxel)
    David Quinn, USC
11:35 am  Question-and-Answer Session
11:40 pm  Chronic Myeloid Leukemia: Overcoming Resistance with New Agents
    Mehrdad Abedi, UC Davis
11:55 am  Question-and-Answer Session
12:00 pm  Micro-RNAs in Oncology
    Guido Marcucci, City of Hope
12:15 am  Question-and-Answer Session
12:20    Post-session Survey

12:25 pm  Closing and Adjourn
HOTEL INFORMATION

THE WESTIN PASADENA
191 N Los Robles Ave., Pasadena, CA 91101
RESERVATIONS: 866.837.4181

The Westin Pasadena welcomes guests with a full complement of facilities and amenities, all designed to ensure you leave feeling better than when you arrived. We prioritize convenience and simplicity with our 24-hour Business Center, where you can put tasks behind you with ease, as well as Concierge services, for professional guidance on enjoying the best Pasadena has to offer. For reenergizing and clearing your mind, take advantage of our light-filled WestinWORKOUT® Fitness Studio and our alluring outdoor heated pool, with gorgeous views.

Enjoy some of the finest views of the San Gabriel Mountains and the Pasadena area from The Westin Pasadena, or step out to partake in the colorful spirit of downtown. Shoppers and food-lovers alike will revel in the remarkable range of options surrounding us. Just a few minutes on foot from the hotel, the Paseo Colorado features premier dining and retail outlets plus a cinema. Less than a mile away, historic Old Pasadena’s charming storefronts house 200 shops plus a wide array of restaurants and night spots.

The Westin is located within walking distance of the Pacific Asia Museum areas, while the California Technical Institute, the historic Tournament of Roses house, and the Norton Simon Museum are all less than two miles away. A ten-minute drive will take you to the resplendent Huntington Library, with its extensive art collections and botanical gardens.

Golf enthusiasts will enjoy the 36-hole, William P. Bell-designed Brookside Golf Club, just a five-minute drive away. The nine-hole Eaton Canyon course is 15 minutes away in the San Gabriel foothills, and Santa Anita Park—a famous thoroughbred racetrack—is equally close by. The Rose Bowl, a world-famous sports and entertainment venue boasting beautiful greenery and cliff sides, is only five minutes away by car.

The Westin Pasadena is offering special rates during this conference of $159 single or double room plus tax, European Plan (no meals). The cutoff date to make reservations is July 18th, 2016, after this date reservations are subject to hotel availability.

Make your hotel reservations by calling 866.837.4181 and use group code “CA Cancer Consortium Conference”

CONFERENCE MANAGEMENT
MEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)
1550 S Dixie Highway Suite 202
Coral Gables, FL 33146
Telephone 305.663.1628
FAX 305.675.2718
Website: www.meccinc.com
Email: tvalls@meccinc.com

Register online at www.meccinc.com under upcoming events.
Recent Advances and New Directions in Cancer Therapy:  
12th Annual California Cancer Consortium Conference  
August 12-14, 2016, The Westin Pasadena, Pasadena, CA

REGISTRATION FORM

Register online at www.meccinc.com or fax to 305.675.2718

Name_________________________________________Degree__________________

Address______________________________________________________________________________________________________________________________

Telephone (    )_______________________________FAX (    )___________________

Email address__________________________________________________________

Specialty______________________________________________________________________________________________________________________________

License Number______________________________State______________________

Type of Practice Private Academic Hospital Other

Registration Fee:

$150 Physician

$50 Optional Fee for Maintenance of Certification Credits (10 ABIM MOC points equivalent to 10 AMA PRA Category 1 Credits will be offered for successful completion of pre- and post-course MOC questionnaires)

$75 Nurse, Nurse Practitioner, Resident, Fellow, Students, Non-physician researchers and staff (e.g., CRAs)

$250 Industry Professional

Refunds must be provided in writing prior to July 8th, 2016. A $50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

Enclosed is my check i/a/of $__________ for the registration of this conference.

I authorize MECC to charge my credit card i/a/o $__________ for the registration of this course using the following credit card.

Name as it appear on the card_________________________________________Exp. Date_________

Card number__________________________________________________________

Authorized signature___________________________________________________
For those requiring special assistance, contact MECC at 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2016.